Initial Results Positive For Valneva/Pfizer's Lyme Disease Vaccine In First Phase II Study

Role Of Infectious Disease Prevention Highlighted

 
• By John Davis

Speciality vaccine biotech Valneva outlines seroconversion rates and safety of candidate Lyme disease vaccine that it is co-developing with partner Pfizer.    

Tick
Tick Bites Transfer The Pathogens That Cause Lyme Disease • Source: Shutterstock

More from Anti-infective

More from Therapy Areas